As this subpopulation of CD276+CECs and changes therein are likely to reflect better potential effects on tumor vasculature than the total number of CECs, further investigation on the frequency of these cells and their association with outcome in patients with cancer is warranted. This evidence concerns the gene CD276 and neoplasm.